TrialScientific reports2023

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.

J Ingwersen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.